The purpose of this study was to examine patient preferences and estimate health state utilities associated with the treatment process of GLP-1 receptor agonists for treatment of T2D, including oral semaglutide and two weekly injectable treatments, dulaglutide [17] and semaglutide [18]. Here, GLP1R is linked to type 2 diabetes mellitus.